PDGFRB and neoplasm: Regorafenib can inhibit a variety of kinases involved in angiogenesis, cell proliferation, and tumor growth as well as the tumor microenvironment, mainly including VEGFR1∼3, KIT, RET, PDGFR-β, and FGFR.